Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 99,181 shares, a decrease of 56.7% from the October 15th total of 229,146 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 738,430 shares, the short-interest ratio is currently 0.1 days.
Oncotelic Therapeutics Stock Performance
OTLC traded up $0.00 during trading hours on Friday, hitting $0.01. The company’s stock had a trading volume of 479,008 shares, compared to its average volume of 460,984. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.04. The firm has a market capitalization of $6.03 million, a PE ratio of 0.02 and a beta of -0.10. The company has a current ratio of 0.08, a quick ratio of 0.08 and a debt-to-equity ratio of 0.01. Oncotelic Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.10.
About Oncotelic Therapeutics
Oncotelic Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer and other serious diseases. Its research includes therapies intended to affect biological pathways involved in tumor growth and the body’s immune response. The company’s lead candidate, OT-101, is an antisense therapy designed to inhibit transforming growth factor beta 2 (TGF-β2). Oncotelic has pursued its development for cancers including glioblastoma and pancreatic cancer; it remains an investigational drug, not an approved treatment.
Further Reading
- Five stocks we like better than Oncotelic Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Oncotelic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncotelic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
